Curated News
By: NewsRamp Editorial Staff
October 05, 2026
Biotech Leader Philip Ashton-Rickardt on When to Pivot in Science
TLDR
- Philip Ashton-Rickardt of BE Therapeutics advises biotech leaders to pivot based on evidence, gaining an edge by avoiding attachment to failing ideas.
- Ashton-Rickardt distinguishes attachment to an idea from attachment to the problem, enabling teams to adapt hypotheses as new data emerges in biotech.
- By admitting uncertainty and prioritizing problem-solving over ego, Ashton-Rickardt fosters scientific cultures that improve patient outcomes through adaptable therapies.
- Philip Ashton-Rickardt, a biotech leader, shares that changing direction in science often signals learning, not failure, and curiosity drives better decisions.
Impact - Why it Matters
In an era of rapid scientific advancement, knowing when to abandon a hypothesis is as critical as knowing when to pursue one. Ashton-Rickardt's emphasis on separating attachment to ideas from attachment to problems can prevent costly delays in drug development, where rigid thinking often leads to dead ends. His call for transparent leadership—acknowledging uncertainty rather than feigning omniscience—builds trust and encourages teams to speak up, which is vital for innovation. As biotech companies race to develop therapies for neurological diseases and cancer, the ability to pivot based on evidence can mean the difference between breakthrough and failure. Ultimately, this approach not only accelerates progress but also fosters a healthier scientific culture that prioritizes solving problems over protecting egos.
Summary
In a career spanning more than three decades, Philip Ashton-Rickardt, Managing Director and Chief Scientific Officer at BE Therapeutics, has learned that scientific leadership hinges on knowing when to persist with an idea and when to pivot. His journey includes professorships at the University of Chicago and Imperial College London, founding Smith Therapeutics, serving as Chief Scientific Officer at Sigilon Therapeutics, advising through Flagship Pioneering, and building Halyard Therapeutics and BE Therapeutics. Across these roles, he has observed how commitment can morph into attachment. "You have to separate attachment to the idea from attachment to the problem," he said. "If the problem is important, there may be several ways to approach it." This distinction is crucial in biotech, where programmes evolve with new data, and changing direction often signals learning, not failure.
Ashton-Rickardt also emphasizes confidence without false certainty. Leaders must provide direction before all questions are answered, but he advocates transparency about unknowns and what would trigger a change. "There is a difference between providing direction and pretending to know the future," he noted. Such honesty fosters team psychological safety, encouraging members to raise concerns and challenge assumptions. His own path—from a working-class UK background to academic science and then back to Boston to start a biotech company—has reinforced the value of curiosity. "The people I enjoy working with tend to ask good questions, even when those questions make the project more complicated," he said.
Currently, Ashton-Rickardt focuses on engineered cell therapies and treatments for neurological and other serious diseases at BE Therapeutics and Halyard Therapeutics, where he is co-founder and CSO. He stresses that conviction must remain tied to evidence: "The goal is not to prove that your first idea was right. The goal is to solve an important problem." This mindset, he believes, enables scientific organizations to adapt as new tools and data reshape therapeutic possibilities.
Source Statement
This curated news summary relied on content distributed by 24-7 Press Release. Read the original source here, Biotech Leader Philip Ashton-Rickardt on When to Pivot in Science
